Cara Therapeutics, Inc.
CARA
Rang in Aktien
#9894
Cara Therapeutics, Inc. is an early-stage biopharmaceutical firm operating... Cara Therapeutics, Inc. is an early-stage biopharmaceutical firm operating primarily within the United States. Its core business involves discovering and commercializing novel drug compounds, with a particular emphasis on addressing itching (pruritus) and pain by selectively modulating kappa opioid receptors. The company's therapeutic pipeline includes potential medicines designed to interact with the body's peripheral nervous system and immune cells. KORSUVA (difelikefalin), an injectable formulation, stands as their flagship product. It is approved for treating moderate-to-severe pruritus linked to chronic kidney disease in adult patients undergoing hemodialysis. Additionally, Cara Therapeutics is advancing an oral version of KORSUVA (difelikefalin) through its pipeline. This oral candidate has successfully completed Phase II clinical trials for relieving pruritus associated with atopic dermatitis and chronic kidney disease not requiring dialysis (NDD-CKD). It is also currently undergoing Phase II evaluation for pruritus related to chronic liver disease (specifically primary biliary cholangitis) and for notalgia paresthetica. The company has established international licensing agreements: one with Maruishi Pharmaceutical Co., Ltd for the development, production, and commercialization of difelikefalin-containing products targeting acute pain and uremic pruritus in Japan, and another with Chong Kun Dang Pharmaceutical Corporation for similar activities concerning difelikefalin products in South Korea. Cara Therapeutics, Inc. was established in 2004 and is headquartered in Stamford, Connecticut.
Aktienkurs
$15.96
Zuletzt synchronisiert: 2025-04-15
Marktkapitalisierung
$875.31M
Veränderung (1 Tag)
-4.14%
Veränderung (1 Jahr)
-0.19%
Land
US
Handel Cara Therapeutics, Inc. (CARA)
Kategorie
Healthcare
Marktkapitalisierung von Cara Therapeutics, Inc.(CARA)
Marktkapitalisierung: $875.31M
Mit Stand October 2026 hat Cara Therapeutics, Inc. eine Marktkapitalisierung von $875.31M. Das macht Cara Therapeutics, Inc. laut unseren Daten zum 9894th wertvollsten Unternehmen der Welt nach Marktkapitalisierung. Die Marktkapitalisierung ist der Gesamtmarktwert aller ausstehenden Aktien eines börsennotierten Unternehmens und wird häufig verwendet, um den Unternehmenswert zu bestimmen.
Marktkapitalisierung von Cara Therapeutics, Inc. von 2018 bis 2026
CARA im Vergleich zu den Top 5 der beliebtesten stocks
| Preis für CARA | Vermögenswert B | Marktkapitalisierung von B | Ergebnisse | |
|---|---|---|---|---|
$3,395,620
$24.33M
|
$5.167T | +21,235,796.41% | ||
|
$3,295,559
$24.33M
|
$5.015T | +20,610,023.16% | ||
|
$2,699,916
$24.33M
|
$4.108T | +16,884,925.87% | ||
|
$2,564,211
$24.33M
|
$3.902T | +16,036,242.67% | ||
|
$1,767,428
$24.33M
|
$2.689T | +11,053,232.26% |
